Krystal Biotech, Inc. $KRYS is S Squared Technology LLC’s 4th Largest Position

S Squared Technology LLC grew its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 12.3% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 109,215 shares of the company’s stock after buying an additional 12,000 shares during the quarter. Krystal Biotech accounts for 6.3% of S Squared Technology LLC’s investment portfolio, making the stock its 4th biggest position. S Squared Technology LLC owned 0.38% of Krystal Biotech worth $15,013,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Krystal Biotech by 173.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 575,506 shares of the company’s stock valued at $103,764,000 after acquiring an additional 365,304 shares during the last quarter. Braidwell LP increased its stake in shares of Krystal Biotech by 99.9% during the first quarter. Braidwell LP now owns 400,744 shares of the company’s stock valued at $72,254,000 after purchasing an additional 200,244 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in Krystal Biotech by 3.0% during the first quarter. Charles Schwab Investment Management Inc. now owns 250,514 shares of the company’s stock valued at $45,168,000 after buying an additional 7,344 shares during the last quarter. Nuveen LLC purchased a new stake in Krystal Biotech during the 1st quarter valued at about $42,223,000. Finally, Woodline Partners LP raised its holdings in Krystal Biotech by 0.4% in the 1st quarter. Woodline Partners LP now owns 222,043 shares of the company’s stock worth $40,034,000 after acquiring an additional 941 shares during the last quarter. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Krystal Biotech Price Performance

Shares of NASDAQ KRYS opened at $197.93 on Monday. The stock has a market capitalization of $5.74 billion, a P/E ratio of 29.67 and a beta of 0.65. Krystal Biotech, Inc. has a 1-year low of $122.80 and a 1-year high of $212.98. The business has a fifty day moving average price of $174.55 and a 200 day moving average price of $153.87.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Monday, November 3rd. The company reported $2.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.12 by $1.54. The company had revenue of $97.80 million for the quarter, compared to analyst estimates of $93.72 million. Krystal Biotech had a return on equity of 19.36% and a net margin of 53.30%. As a group, equities research analysts anticipate that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on KRYS. Guggenheim set a $224.00 price target on shares of Krystal Biotech and gave the stock a “buy” rating in a research note on Friday, October 17th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Krystal Biotech in a report on Wednesday, October 8th. HC Wainwright reiterated a “buy” rating and set a $240.00 target price on shares of Krystal Biotech in a research report on Monday, September 15th. Bank of America boosted their target price on Krystal Biotech from $182.00 to $255.00 and gave the stock a “buy” rating in a research report on Friday, October 17th. Finally, Citigroup upped their target price on shares of Krystal Biotech from $166.00 to $198.00 and gave the company a “neutral” rating in a research report on Tuesday, November 4th. Six research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $228.14.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).